Finatem sells Bärbel Drexel to the Belgian healthcare investor Damier Group

Finatem, an independent investment firm with a focus on SMEs in German speaking countries, has sold its portfolio company Bärbel Drexel GmbH („Bärbel Drexel“), Baar, to the Belgium based healthcare Investor Damier N.V. („Damier“), Kortrijk, Belgien.

Based on its longtime experience and competence in the field of naturopathy Bärbel Drexel develops, produces and distributes nutritional supplements and natural cosmetics with the highest therapeutically effectiveness. The company utilises solely natural ingredients for its products of highest quality – produced and developed in its own manufactory in Baar. Its creative R&D department enables Bärbel Drexel continuously to successfully position innovative new products based on scientific knowledge, like algae based nutritional supplements (such as Astaxanthin and Spirulina) in the market. It places trust and transparency as a basis for high customer satisfaction and loyalty in the center of its activities. The products are marketed directly via the sales channels mail-order, online and teleshopping. In the last few years the company succeeded to significantly grow in particular in online- and mail-order business. In 2016 the company employed 80 people and realised sales to customers of EUR 36 million.

Damier, a privately owned Belgium Investment company primarily focuses on targets in Europe active in branded consumer fields and more specifically in the consumer healthcare sector.

The parties agreed not to reveal the transaction details.

Finatem was advised by the Quarton International on this transaction. Legal and tax advisor to Finatem was Otto Mittag Fontane.